Characteristic | With GnRH N (%) | Without GnRH N (%) | p value* |
---|---|---|---|
Age | |||
Median | 64 | 63 | 0.79 |
Range | 24–82 | 29–76 | |
ECOG PS | |||
Median | 1 | 1 | 0.88 |
Range | 0–2 | 0–2 | |
Hormone receptor status | |||
Positive | 32 (86.5) | 19 (82.6) | 0.99 |
Negative | 2 (5.5) | 2 (8.7) | |
Unknown | 3 (8) | 2 (8.7) | |
Adjuvant systemic therapy | |||
Yes | 19 (51) | 10 (43.5) | 0.60 |
No | 18 (49) | 13 (56.5) | |
Prior therapy for metastatic disease | |||
Yes | 9 (24) | 7 (30.5) | 0.99 |
No | 28 (76) | 16 (69.5) | |
Subsequent lines of CT | |||
Median | 1 | 1 | 0.72 |
Range | 1–2 | 1–2 | |
Subsequent lines of HT | |||
Median | 1 | 1 | 0.85 |
Range | 1–3 | 1–3 | |
Dominant disease site | |||
Viscera | 24 (64.9) | 14 (60.8) | |
Bone | 9 (24.3) | 8 (34.8) | 0.98 |
Soft-tissue | 4 (10.8) | 1 (4.4) | |
Number of disease sites | |||
1 | 11 (29.7) | 10 (43.4) | |
2 | 21 (56.7) | 9 (39.1) | 0.99 |
≥ 3 | 5 (13.6) | 4 (17.5) |